Tonix Pharmaceuticals Holding TNXP Stock
Tonix Pharmaceuticals Holding Price Chart
Tonix Pharmaceuticals Holding TNXP Financial and Trading Overview
Tonix Pharmaceuticals Holding stock price | 0.17 USD |
Previous Close | 1.82 USD |
Open | 1.88 USD |
Bid | 0 USD x 3200 |
Ask | 0 USD x 1400 |
Day's Range | 1.84 - 1.99 USD |
52 Week Range | 1.62 - 14 USD |
Volume | 440.4K USD |
Avg. Volume | 223.17K USD |
Market Cap | 19.85M USD |
Beta (5Y Monthly) | 2.180985 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.82 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 40.63 USD |
TNXP Valuation Measures
Enterprise Value | -52129544 USD |
Trailing P/E | N/A |
Forward P/E | -0.24396442 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 0.1182703 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | 0.444 |
Trading Information
Tonix Pharmaceuticals Holding Stock Price History
Beta (5Y Monthly) | 2.180985 |
52-Week Change | -82.64% |
S&P500 52-Week Change | 20.43% |
52 Week High | 14 USD |
52 Week Low | 1.62 USD |
50-Day Moving Average | 2.47 USD |
200-Day Moving Average | 3.73 USD |
TNXP Share Statistics
Avg. Volume (3 month) | 223.17K USD |
Avg. Daily Volume (10-Days) | 285.72K USD |
Shares Outstanding | 10.34M |
Float | 10.34M |
Short Ratio | 2.88 |
% Held by Insiders | N/A |
% Held by Institutions | N/A |
Shares Short | 996.88K |
Short % of Float | 9.64% |
Short % of Shares Outstanding | 9.64% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 16:100 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -37.10% |
Return on Equity (ttm) | -62.56% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -117474000 USD |
Net Income Avi to Common (ttm) | -123465000 USD |
Diluted EPS (ttm) | -14.39 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 71.98M USD |
Total Cash Per Share (mrq) | 6.96 USD |
Total Debt (mrq) | 1.03M USD |
Total Debt/Equity (mrq) | 0.62 USD |
Current Ratio (mrq) | 6.404 |
Book Value Per Share (mrq) | 16.234 |
Cash Flow Statement
Operating Cash Flow (ttm) | -99918000 USD |
Levered Free Cash Flow (ttm) | -94762128 USD |
Profile of Tonix Pharmaceuticals Holding
Country | United States |
State | NJ |
City | Chatham |
Address | 26 Main Street |
ZIP | 07928 |
Phone | 862 799 8599 |
Website | https://www.tonixpharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 117 |
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, develops therapeutics and vaccines to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed to treat autoimmune conditions. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; and TNX-102 SL, a CNS product candidate to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a recombinant protein enzyme to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Q&A For Tonix Pharmaceuticals Holding Stock
What is a current TNXP stock price?
Tonix Pharmaceuticals Holding TNXP stock price today per share is 0.17 USD.
How to purchase Tonix Pharmaceuticals Holding stock?
You can buy TNXP shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Tonix Pharmaceuticals Holding?
The stock symbol or ticker of Tonix Pharmaceuticals Holding is TNXP.
Which industry does the Tonix Pharmaceuticals Holding company belong to?
The Tonix Pharmaceuticals Holding industry is Biotechnology.
How many shares does Tonix Pharmaceuticals Holding have in circulation?
The max supply of Tonix Pharmaceuticals Holding shares is 95.54M.
What is Tonix Pharmaceuticals Holding Price to Earnings Ratio (PE Ratio)?
Tonix Pharmaceuticals Holding PE Ratio is now.
What was Tonix Pharmaceuticals Holding earnings per share over the trailing 12 months (TTM)?
Tonix Pharmaceuticals Holding EPS is -3.82 USD over the trailing 12 months.
Which sector does the Tonix Pharmaceuticals Holding company belong to?
The Tonix Pharmaceuticals Holding sector is Healthcare.
Tonix Pharmaceuticals Holding TNXP included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 17019.88 USD — |
+0.59
|
5.94B USD — | 16917.51 USD — | 17032.66 USD — | — - | 5.94B USD — |
NASDAQ Composite Total Return I XCMP | 20705.72 USD — |
+0.59
|
— — | 20581.18 USD — | 20721.26 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4363.67 USD — |
-1.28
|
— — | 4335.6 USD — | 4436.05 USD — | — - | — — |
NASDAQ HealthCare IXHC | 978.74 USD — |
-1.03
|
— — | 973.64 USD — | 990.74 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}